Daniel J. O'connor - Net Worth and Insider Trading

Daniel J. O'connor Net Worth

The estimated net worth of Daniel J. O'connor is at least $10 Million dollars as of 2024-05-12. Daniel J. O'connor is the President and CEO of Ambrx Biopharma Inc and owns about 342,845 shares of Ambrx Biopharma Inc (AMAM) stock worth over $10 Million. Daniel J. O'connor is the Director of Seelos Therapeutics Inc and owns about 533 shares of Seelos Therapeutics Inc (SEEL) stock worth over $143. Daniel J. O'connor is also the CEO of Advaxis Inc and owns about 246 shares of Advaxis Inc (ADXS) stock worth over $108. Besides these, Daniel J. O'connor also holds OncoSec Medical Inc (ONCSQ) . Details can be seen in Daniel J. O'connor's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Daniel J. O'connor has not made any transactions after 2023-10-27 and currently still holds the listed stock(s).

Transaction Summary of Daniel J. O'connor

Daniel J. O'connor Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Daniel J. O'connor owns 7 companies in total, including Seelos Therapeutics Inc (SEEL) , Advaxis Inc (ADXS) , and OncoSec Medical Inc (ONCSQ) among others .

Click here to see the complete history of Daniel J. O'connor’s form 4 insider trades.

Insider Ownership Summary of Daniel J. O'connor

Ticker	Comapny	Transaction Date	Type of Owner
SEEL	Seelos Therapeutics Inc	2022-06-01	director
ADXS	Advaxis Inc	2016-11-02	SVP & Legal & Business Dev Off
ONCSQ	OncoSec Medical Inc	2021-04-30	director
		2021-12-20	director & Chief Executive Officer
		2023-07-05	director & President and CEO
		2021-12-20	director & Chief Executive Officer
		2023-10-27	director & President and CEO

Daniel J. O'connor Latest Holdings Summary

Daniel J. O'connor currently owns a total of 4 stocks. Among these stocks, Daniel J. O'connor owns 342,845 shares of Ambrx Biopharma Inc (AMAM) as of October 27, 2023, with a value of $10 Million and a weighting of 100%. Daniel J. O'connor owns 533 shares of Seelos Therapeutics Inc (SEEL) as of June 1, 2022, with a value of $143 and a weighting of 0%. Daniel J. O'connor also owns 246 shares of Advaxis Inc (ADXS) as of November 2, 2016, with a value of $108 and a weighting of 0%. The other 1 stocks OncoSec Medical Inc (ONCSQ) have a combined weighting of 0% among all his current holdings.

Latest Holdings of Daniel J. O'connor

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
AMAM	Ambrx Biopharma Inc	2023-10-27	342,845	28.00	9,599,660
SEEL	Seelos Therapeutics Inc	2022-06-01	533	0.27	143
ADXS	Advaxis Inc	2016-11-02	246	0.44	108
ONCSQ	OncoSec Medical Inc	2021-04-30	4,368	0.00	1

Holding Weightings of Daniel J. O'connor

Daniel J. O'connor Form 4 Trading Tracker

According to the SEC Form 4 filings, Daniel J. O'connor has made a total of 1 transactions in Ambrx Biopharma Inc (AMAM) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Ambrx Biopharma Inc is the sale of 50,012 shares on October 27, 2023, which brought Daniel J. O'connor around $491,118.

According to the SEC Form 4 filings, Daniel J. O'connor has made a total of 1 transactions in Seelos Therapeutics Inc (SEEL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Seelos Therapeutics Inc is the acquisition of 533 shares on June 1, 2022, which cost Daniel J. O'connor around $9,760.

According to the SEC Form 4 filings, Daniel J. O'connor has made a total of 0 transactions in Advaxis Inc (ADXS) over the past 5 years. The most-recent trade in Advaxis Inc is the sale of 7 shares on November 2, 2016, which brought Daniel J. O'connor around $68,557.

More details on Daniel J. O'connor's insider transactions can be found in the Insider Trading History of Daniel J. O'connor table.

Insider Trading History of Daniel J. O'connor

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Daniel J. O'connor Trading Performance

GuruFocus tracks the stock performance after each of Daniel J. O'connor's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel J. O'connor is 22.68%. GuruFocus also compares Daniel J. O'connor's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel J. O'connor within 3 months outperforms 3 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Daniel J. O'connor's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Daniel J. O'connor

Average Return

Average return per transaction

Outperforming Transactions

2 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	1.76
Relative Return to S&P 500(%)	2.4

Daniel J. O'connor Ownership Network

Ownership Network List of Daniel J. O'connor

No Data

Ownership Network Relation of Daniel J. O'connor

Daniel J. O'connor Owned Company Details

What does Seelos Therapeutics Inc do?

Who are the key executives at Seelos Therapeutics Inc?

Daniel J. O'connor is the director of Seelos Therapeutics Inc. Other key executives at Seelos Therapeutics Inc include director & See Remarks Raj Mehra , Chief Financial Officer Michael Joseph Golembiewski , and director & CEO & Secretary Richard W Pascoe .

Seelos Therapeutics Inc (SEEL) Insider Trades Summary

Over the past 18 months, Daniel J. O'connor made no insider transaction in Seelos Therapeutics Inc (SEEL). Other recent insider transactions involving Seelos Therapeutics Inc (SEEL) include a net purchase of 83,000 shares made by Michael Joseph Golembiewski , and a net purchase of 75,757 shares made by Raj Mehra .

In summary, during the past 3 months, insiders sold 0 shares of Seelos Therapeutics Inc (SEEL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Seelos Therapeutics Inc (SEEL) were sold and 158,757 shares were bought by its insiders, resulting in a net purchase of 158,757 shares.

Seelos Therapeutics Inc (SEEL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seelos Therapeutics Inc Insider Transactions

No Available Data

What does Advaxis Inc do?

Who are the key executives at Advaxis Inc?

Daniel J. O'connor is the SVP & Legal & Business Dev Off of Advaxis Inc. Other key executives at Advaxis Inc include Chief Financial Officer Roy Golan , 10 percent owner Israel Biotech Fund Gp Partners Ii, L.p. , and 10 percent owner Israel Biotech Fund Ii, L.p. .

Advaxis Inc (ADXS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Advaxis Inc (ADXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Advaxis Inc (ADXS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Advaxis Inc (ADXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Advaxis Inc Insider Transactions

No Available Data

What does OncoSec Medical Inc do?

Who are the key executives at OncoSec Medical Inc?

Daniel J. O'connor is the director of OncoSec Medical Inc. Other key executives at OncoSec Medical Inc include Principal Accounting Officer Robert J Delaversano , President and CEO Robert H. Arch , and Chief Financial Officer George Chi .

OncoSec Medical Inc (ONCSQ) Insider Trades Summary

Over the past 18 months, Daniel J. O'connor made no insider transaction in OncoSec Medical Inc (ONCSQ). Other recent insider transactions involving OncoSec Medical Inc (ONCSQ) include a net sale of 40 shares made by Robert J Delaversano ,

In summary, during the past 3 months, insiders sold 0 shares of OncoSec Medical Inc (ONCSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 40 shares of OncoSec Medical Inc (ONCSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 40 shares.

OncoSec Medical Inc (ONCSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

OncoSec Medical Inc Insider Transactions

No Available Data

What does Larkspur Health Acquisition Corp do?

Who are the key executives at Larkspur Health Acquisition Corp?

Daniel J. O'connor is the director & Chief Executive Officer of Larkspur Health Acquisition Corp. Other key executives at Larkspur Health Acquisition Corp include director & Chief Financial Officer David S. Briones , 10 percent owner A.g.p. / Alliance Global Partners Corp. , and 10 percent owner Larkspur Health Llc .

Larkspur Health Acquisition Corp (LSPR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Larkspur Health Acquisition Corp (LSPR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Larkspur Health Acquisition Corp (LSPR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Larkspur Health Acquisition Corp (LSPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Larkspur Health Acquisition Corp Insider Transactions

No Available Data

What does Ambrx Biopharma Inc do?

Who are the key executives at Ambrx Biopharma Inc?

Daniel J. O'connor is the director & President and CEO of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include 10 percent owner Cormorant Asset Management, Lp , Chief Financial Officer Sonja Nelson , and 10 percent owner Darwin Global Master Fund, Ltd. .

Ambrx Biopharma Inc (AMAM) Insider Trades Summary

Over the past 18 months, Daniel J. O'connor made no insider transaction in Ambrx Biopharma Inc (AMAM). Other recent insider transactions involving Ambrx Biopharma Inc (AMAM) include a net purchase of 10,965,823 shares made by Cormorant Asset Management, Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ambrx Biopharma Inc (AMAM) were sold and 10,965,823 shares were bought by its insiders, resulting in a net purchase of 10,965,823 shares.

Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ambrx Biopharma Inc Insider Transactions

No Available Data

What does ZyVersa Therapeutics Inc do?

Who are the key executives at ZyVersa Therapeutics Inc?

Daniel J. O'connor is the director & Chief Executive Officer of ZyVersa Therapeutics Inc. Other key executives at ZyVersa Therapeutics Inc include Chief Medical Officer Pablo A. Guzman , director & Chief Executive Officer Stephen C. Glover , and Chief Scientific Officer Labella Nicholas A. Jr. .

ZyVersa Therapeutics Inc (ZVSA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZyVersa Therapeutics Inc (ZVSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZyVersa Therapeutics Inc (ZVSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZyVersa Therapeutics Inc (ZVSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZyVersa Therapeutics Inc Insider Transactions

No Available Data

What does Ambrx Biopharma Inc do?

Who are the key executives at Ambrx Biopharma Inc?

Daniel J. O'connor is the director & President and CEO of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include Chief Financial Officer Sonja Nelson , 10 percent owner Cormorant Asset Management, Lp , and 10 percent owner Bihua Chen .

Ambrx Biopharma Inc (AMAM) Insider Trades Summary

Over the past 18 months, Daniel J. O'connor made 1 insider transaction in Ambrx Biopharma Inc (AMAM) with a net sale of 50,012. Other recent insider transactions involving Ambrx Biopharma Inc (AMAM) include a net purchase of 1,307,311 shares made by Cormorant Asset Management, Lp , a net sale of 12,778 shares made by Sonja Nelson ,

In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 62,790 shares of Ambrx Biopharma Inc (AMAM) were sold and 1,307,311 shares were bought by its insiders, resulting in a net purchase of 1,244,521 shares.

Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ambrx Biopharma Inc Insider Transactions

No Available Data

Daniel J. O'connor Mailing Address

Above is the net worth, insider trading, and ownership report for Daniel J. O'connor. You might contact Daniel J. O'connor via mailing address: C/o Seelos Therapeutics, Inc., 300 Park Avenue, 12th Floor, New York Ny 10022.

Discussions on Daniel J. O'connor

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.